vs
简柏特（G）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
简柏特的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 10.8%，领先1.9%），Revvity同比增速更快（5.9% vs 5.6%），简柏特自由现金流更多（$269.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 8.0%）
简柏特是全球领先的信息技术服务、咨询及外包提供商，总部位于美国纽约，最初成立于印度古尔冈，法定注册地为百慕大。集团现有员工超12.5万名，服务覆盖全球30多个国家，于纽交所上市，2023年总营收达44.8亿美元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
G vs RVTY — 直观对比
营收规模更大
G
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出0.2%
5.6%
净利率更高
RVTY
高出1.9%
10.8%
自由现金流更多
G
多$107.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $143.1M | $98.4M |
| 毛利率 | 36.6% | — |
| 营业利润率 | 14.8% | 14.5% |
| 净利率 | 10.8% | 12.7% |
| 营收同比 | 5.6% | 5.9% |
| 净利润同比 | 0.8% | 3.9% |
| 每股收益（稀释后） | $0.82 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
净利润GRVTY
| Q4 25 | $143.1M | $98.4M | ||
| Q3 25 | $145.8M | $46.7M | ||
| Q2 25 | $132.7M | $53.9M | ||
| Q1 25 | $130.9M | $42.2M | ||
| Q4 24 | $141.9M | $94.6M | ||
| Q3 24 | $132.8M | $94.4M | ||
| Q2 24 | $122.0M | $55.4M | ||
| Q1 24 | $116.9M | $26.0M |
毛利率GRVTY
| Q4 25 | 36.6% | — | ||
| Q3 25 | 36.4% | 53.6% | ||
| Q2 25 | 35.9% | 54.5% | ||
| Q1 25 | 35.3% | 56.5% | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 35.6% | 56.3% | ||
| Q2 24 | 35.4% | 55.7% | ||
| Q1 24 | 35.0% | 54.6% |
营业利润率GRVTY
| Q4 25 | 14.8% | 14.5% | ||
| Q3 25 | 14.8% | 11.7% | ||
| Q2 25 | 14.3% | 12.6% | ||
| Q1 25 | 15.1% | 10.9% | ||
| Q4 24 | 15.2% | 16.3% | ||
| Q3 24 | 15.0% | 14.3% | ||
| Q2 24 | 14.5% | 12.4% | ||
| Q1 24 | 14.1% | 6.8% |
净利率GRVTY
| Q4 25 | 10.8% | 12.7% | ||
| Q3 25 | 11.3% | 6.7% | ||
| Q2 25 | 10.6% | 7.5% | ||
| Q1 25 | 10.8% | 6.4% | ||
| Q4 24 | 11.4% | 13.0% | ||
| Q3 24 | 11.0% | 13.8% | ||
| Q2 24 | 10.4% | 8.0% | ||
| Q1 24 | 10.3% | 4.0% |
每股收益（稀释后）GRVTY
| Q4 25 | $0.82 | $0.86 | ||
| Q3 25 | $0.83 | $0.40 | ||
| Q2 25 | $0.75 | $0.46 | ||
| Q1 25 | $0.73 | $0.35 | ||
| Q4 24 | $0.80 | $0.77 | ||
| Q3 24 | $0.74 | $0.77 | ||
| Q2 24 | $0.67 | $0.45 | ||
| Q1 24 | $0.64 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $2.5B | $7.3B |
| 总资产 | $5.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.60× | — |
8季度趋势，按日历期对齐
现金及短期投资GRVTY
| Q4 25 | $1.2B | $919.9M | ||
| Q3 25 | $740.8M | $931.4M | ||
| Q2 25 | $663.3M | $991.8M | ||
| Q1 25 | $561.6M | $1.1B | ||
| Q4 24 | $671.6M | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $914.2M | $2.0B | ||
| Q1 24 | $478.4M | $1.7B |
总债务GRVTY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.2B | — |
股东权益GRVTY
| Q4 25 | $2.5B | $7.3B | ||
| Q3 25 | $2.5B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
总资产GRVTY
| Q4 25 | $5.8B | $12.2B | ||
| Q3 25 | $5.4B | $12.1B | ||
| Q2 25 | $5.3B | $12.4B | ||
| Q1 25 | $4.9B | $12.4B | ||
| Q4 24 | $5.0B | $12.4B | ||
| Q3 24 | $5.3B | $12.8B | ||
| Q2 24 | $5.2B | $13.4B | ||
| Q1 24 | $4.7B | $13.4B |
负债/权益比GRVTY
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $286.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $269.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 20.4% | 21.0% |
| 资本支出强度资本支出/营收 | 1.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.00× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $734.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GRVTY
| Q4 25 | $286.7M | $182.0M | ||
| Q3 25 | $308.4M | $138.5M | ||
| Q2 25 | $177.4M | $134.3M | ||
| Q1 25 | $40.4M | $128.2M | ||
| Q4 24 | $203.2M | $174.2M | ||
| Q3 24 | $228.5M | $147.9M | ||
| Q2 24 | $209.3M | $158.6M | ||
| Q1 24 | $-25.6M | $147.6M |
自由现金流GRVTY
| Q4 25 | $269.0M | $161.8M | ||
| Q3 25 | $292.0M | $120.0M | ||
| Q2 25 | $155.1M | $115.5M | ||
| Q1 25 | $18.5M | $112.2M | ||
| Q4 24 | $183.5M | $149.8M | ||
| Q3 24 | $208.7M | $125.6M | ||
| Q2 24 | $190.0M | $136.6M | ||
| Q1 24 | $-49.6M | $129.7M |
自由现金流率GRVTY
| Q4 25 | 20.4% | 21.0% | ||
| Q3 25 | 22.6% | 17.2% | ||
| Q2 25 | 12.4% | 16.0% | ||
| Q1 25 | 1.5% | 16.9% | ||
| Q4 24 | 14.7% | 20.5% | ||
| Q3 24 | 17.2% | 18.4% | ||
| Q2 24 | 16.2% | 19.7% | ||
| Q1 24 | -4.4% | 20.0% |
资本支出强度GRVTY
| Q4 25 | 1.3% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.6% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率GRVTY
| Q4 25 | 2.00× | 1.85× | ||
| Q3 25 | 2.11× | 2.97× | ||
| Q2 25 | 1.34× | 2.49× | ||
| Q1 25 | 0.31× | 3.03× | ||
| Q4 24 | 1.43× | 1.84× | ||
| Q3 24 | 1.72× | 1.57× | ||
| Q2 24 | 1.72× | 2.87× | ||
| Q1 24 | -0.22× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
G
| High Tech And Manufacturing | $525.3M | 40% |
| Consumer And Healthcare | $445.8M | 34% |
| Financial Services | $348.2M | 26% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
